戊聚糖多硫酸钠(爱泌罗)用法用量？

Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a chronic inflammatory bladder disease that clinically manifests as pain or pelvic discomfort related to bladder filling, accompanied by lower urinary tract symptoms such as urinary frequency or urgency. There are obvious differences in the reported incidence rates around the world. For example, the incidence rate in Europe and the United States can reach 2.7% to 6.5%, and the Asia-Pacific region is about 0.10% to 0.26%. The proportion of female patients is higher than that of male patients. (Elmiron) is the only FDA-approved oral drug for the treatment of interstitial cystitis. It is launched by Ortho-McNeil-Janssen Pharmaceuticals, Inc. in the United States and has not yet been launched in China. So, what is the usage and dosage of Pentosan Polysulfate Sodium (Amirol)?

Pentosan Polysulfate Sodium (Amirol) Usage and Dosage

300 mg/day, take 1 100 mg capsule orally 3 times daily. Capsules should be taken with water at least 1 hour before or 2 hours after a meal. Patients receiving ELMIRON should be re-evaluated after 3 months. If improvement does not occur and there are no limiting adverse events, ELMIRON® can be continued for 3 months. The clinical value and risks of continuing treatment in patients whose pain has not improved at 6 months are unclear.

Pentosan polysulfate sodium (Amirol) drug overdose

No overdose has been reported. Depending on the pharmacodynamics of the drug, toxicity may manifest as anticoagulation, bleeding, thrombocytopenia, liver function abnormalities, and gastric upset. (See Clinical Pharmacology and Precautions section.) In one clinical trial at a daily dose of 900 mg for 32 weeks (n = 127), rectal bleeding was reported as an adverse event in 15% of patients. In a clinical trial involving 51 patients in the ELMIRON® group and 49 patients in the placebo group, 11.8% of patients reported elevated liver function tests as an adverse event when ELMIRON® was administered at a daily dose of 900 mg for 16 weeks.

2% of patients in the ELMIRON ® group and placebo group. If an acute drug overdose occurs, the patient should be gastric lavaged if possible, carefully observed, and given symptomatic and supportive treatment.

Recommended related articles: